Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $21.9 million.

  • UNITED THERAPEUTICS's Depreciation & Amortization (CF) rose 14.66% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.5 million, marking a year-over-year increase of 24.06%. This contributed to the annual value of $72.5 million for FY2024, which is 36.28% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Depreciation & Amortization (CF) stood at $21.9 million, which was up 3.79% from $21.1 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Depreciation & Amortization (CF)'s 5-year high stood at $21.9 million during Q3 2025, with a 5-year trough of $12.4 million in Q2 2021.
  • In the last 3 years, UNITED THERAPEUTICS's Depreciation & Amortization (CF) had a median value of $18.7 million in 2024 and averaged $17.1 million.
  • In the last 5 years, UNITED THERAPEUTICS's Depreciation & Amortization (CF) declined by 3.82% in 2021 and then skyrocketed by 44.96% in 2024.
  • UNITED THERAPEUTICS's Depreciation & Amortization (CF) (Quarterly) stood at $12.6 million in 2021, then increased by 4.76% to $13.2 million in 2022, then climbed by 3.79% to $13.7 million in 2023, then soared by 43.80% to $19.7 million in 2024, then climbed by 14.66% to $21.9 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $21.9 million for Q3 2025, versus $21.1 million for Q2 2025 and $19.8 million for Q1 2025.